Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, has expanded its original agreement with Endoceutics to commercialise Intrarosa® (prasterone) in Australia.
Lupin Pharma, a subsidiary of global pharma major Lupin Ltd, today announced a partnership with Endoceutics, a women’s health focused innovative Canadian biotech company, to commercialize INTRAROSA® in Canada.
Quebec City, Canada; Endoceutics announces that the U.S. commercial rights for its flagship product, INTRAROSA®, were transferred to Millicent Pharma following a divestiture process announced in January 2020 by AMAG Pharmaceuticals.
Quebec City, Canada; Endoceutics is happy to announce the approval of INTRAROSA by Health Canada for the treatment of postmenopausal vulvovaginal atrophy.
Québec City, Canada; Endoceutics announced today that Dennis Turpin, President and Chief Executive Officer of Endoceutics, is scheduled to present an overview of the company at the Bloom Burton & Co. Healthcare Investor Conference.
Québec City, Canada, March 27, 2019 – Endoceutics Inc., Université Laval, and CHU de Québec-Université Laval (CHU de Québec-UL) are pleased to announce that they have reached an agreement to resolve all their disputes with respect to economic benefits deriving from research. Université Laval and CHU de Québec-UL will share in the anticipated economic benefits associated with Intrarosa™.
Quebec City, January 17, 2019 – It is with great sadness that Endoceutics management announces the death of its president and founder Dr. Fernand Labrie at the age of 81.